Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
8/5/2009 9:10:49 AM
More...
|
Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
3/24/2009 9:37:59 AM
More...
|
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
11/20/2008 7:47:42 AM
More...
|
Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
6/9/2008 8:18:54 AM
More...
|
Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis; Milestone triggers $28.3M Second-tranche Investment
4/2/2008 6:44:43 AM
More...
|
Karo Bio AB Reacquires Rights to SARM Compounds from Radius
2/28/2008 9:38:07 AM
More...
|
Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes
1/30/2008 7:46:11 AM
More...
|
Radius Raises $57.5 Million in Second Private Financing Round
4/2/2007 9:43:14 AM
More...
|
Radius Appoints Nick Harvey Senior Vice President And Chief Financial Officer
1/2/2007 6:23:43 PM
More...
|
Radius And Karo Bio AB Announce Licensing Agreement For Novel SARM Compounds
9/12/2006 1:57:27 PM
More...
|
|